Immune checkpoint inhibitor (keytruda, opdivo, yervoy, tecentriq, imfinzi, libtayo) denied as non-formulary by UnitedHealthcare?

UnitedHealthcare covers immune checkpoint inhibitors (Keytruda/pembrolizumab, Opdivo/nivolumab, Yervoy/ipilimumab, Tecentriq/atezolizumab, Imfinzi/durvalumab, Libtayo/cemiplimab, and related agents) under the medical benefit when prescribed for cancer indications. This policy provides parameters for coverage of injectable oncology medications, including therapeutic radiopharmaceuticals, covered under the medical benefit based upon the National Comprehensive Cancer Network (NCCN) Drugs & Biologics Compendium, which lists appropriate drugs and biologics for specific cancers using US Food and Drug Administration (FDA)-approved disease indications and specific NCCN panel recommendations. UnitedHealthcare recognizes indications listed in the NCCN Drugs and Biologics Compendium with Categories of Evidence and Consensus of 1, 2A, and 2B as proven and medically necessary, and Category 3 as unproven and not medically necessary. Coverage is provided for the UnitedHealthcare preferred oncology product contingent on the diagnosis-specific criteria; coverage for any non-preferred product is contingent on both the Preferred Product Criteria and Diagnosis-Specific Criteria, and members new to therapy are required to use the preferred product unless they meet exception criteria. Preferred/non-preferred designations vary by indication—for example, in non-small cell lung cancer Keytruda Qlex is preferred; in head and neck cancers Keytruda Qlex is non-preferred; and in squamous cell skin cancer Libtayo is preferred while Keytruda, Keytruda Qlex, Opdivo, Opdivo Qvantig, and Unloxcyt are non-preferred. To qualify for a non-preferred product, the patient must have a history of intolerance or contraindication to a UnitedHealthcare preferred oncology product, and the physician must attest that the same intolerance, contraindication, or adverse event would not be expected with the non-preferred product. Keytruda is administered through the medical benefit but specialty pharmacy distribution is required: UnitedHealthcare classifies Keytruda as a specialty medication requiring prior authorization through OptumRx, typically placed on a high-cost specialty tier (Tier 5). Prior authorization is required, with reauthorization on a periodic basis, and specific PD-L1 expression thresholds (e.g., ≥50% for monotherapy first-line NSCLC) apply per the NCCN/FDA labels referenced in the policy.

- **Cite NCCN Category 1/2A recommendation for the exact indication**: UHC's own policy binds coverage to NCCN Compendium recommendations of Category 1, 2A, or 2B as proven and medically necessary . Quote the specific NCCN guideline page and category (e.g., NCCN NSCLC Guidelines list pembrolizumab + chemo as Category 1 for first-line metastatic non-squamous NSCLC; KEYNOTE-189 trial). - **Reference pivotal trial data supporting the FDA label**: For Keytruda in NSCLC cite KEYNOTE-024 (PD-L1 ≥50% monotherapy) and KEYNOTE-189/407 (combo with chemo); for Opdivo+Yervoy cite CheckMate-227/9LA; for Libtayo cite EMPOWER-Lung-1 and EMPOWER-CSCC-1; for Imfinzi cite PACIFIC (stage III NSCLC after chemoradiation); for Tecentriq cite IMpower150/133. - **Document preferred-product step therapy was met or is contraindicated**: Provide chart notes showing prior trial of the UHC preferred ICI with progression, intolerance, or a contraindication (e.g., active autoimmune disease, hypersensitivity), satisfying UHC's exception pathway as history of intolerance or contraindication to one of the UnitedHealthcare's preferred oncology products, and physician attests that the same intolerance, contraindication, or adverse event would not be expected to occur with the respective non-preferred product. - **Submit biomarker results**: Attach the PD-L1 IHC report (22C3/SP263), MSI/MMR or TMB testing report, and tumor histology confirming the FDA-labeled indication; for monotherapy NSCLC confirm PD-L1 expression positive ≥ 50% . - **Invoke ASCO and NCCN consensus**: ASCO Clinical Practice Guidelines (e.g., ASCO/ESMO guidelines for metastatic NSCLC, melanoma, RCC, HNSCC, urothelial carcinoma) concur with NCCN on ICI use; cite specific guideline year and recommendation grade. - **Cite UHC's medical-benefit step therapy carve-outs**: Continuation-of-therapy provisions apply when the member has been receiving the ICI; reference continuation of prior therapy within the past 365 days as grounds for approval without re-trying the preferred agent. - **Escalate to external/independent review with policy language**: Per practitioner experience, external reviews succeed when patients include a detailed timeline showing how UnitedHealthcare's denial contradicts their own published criteria, and independent medical reviewers appreciate clear, point-by-point rebuttals that reference the plan's policy language directly.

## UnitedHealthcare Non-Formulary Denial — Immune Checkpoint Inhibitors

A UnitedHealthcare "non-formulary" denial on an immune checkpoint inhibitor (ICI) is rarely a true formulary exclusion — it is almost always a non-preferred product determination under the Oncology Medication Clinical Coverage – UnitedHealthcare Commercial Medical Benefit Drug Policy (Effective 04/01/2026). The distinction matters: a non-preferred denial is procedurally a step-therapy/preferred-product enforcement action, and it carries a statutory override pathway that a true formulary exclusion does not.

Under the policy, UHC layers two gates on every ICI request: (1) Diagnosis-Specific Criteria tied to the NCCN Drugs & Biologics Compendium (Categories 1, 2A, 2B proven; Category 3 unproven), and (2) Preferred Product Criteria when a non-preferred ICI is requested. Preferred designations are indication-specific — Keytruda Qlex is preferred in NSCLC but non-preferred in head/neck; Libtayo is preferred in cutaneous squamous cell while Keytruda, Opdivo, and Unloxcyt are non-preferred for that same diagnosis. Reviewers routinely conflate "non-preferred" with "non-formulary," generating a denial letter that misstates the basis of adverse benefit determination — itself a 29 CFR §2560.503-1(g) disclosure violation appealable on procedural grounds alone.

The appeal must surgically attack the preferred-product gate. UHC's exception criteria require documentation of (a) intolerance, contraindication, or adverse event to the preferred ICI, AND (b) prescriber attestation that the same reaction would not be expected with the non-preferred agent. Build the record around immune-related adverse events (irAEs) — pneumonitis, colitis, hepatitis, endocrinopathies — with grade per CTCAE v5.0, dates, and rechallenge contraindication per ASCO irAE guidelines. If the patient is treatment-naïve, anchor the request to FDA-label-distinguishing biomarkers: PD-L1 TPS ≥50% for first-line monotherapy NSCLC, MSI-H/dMMR status, TMB-H ≥10 mut/Mb, or histology-specific NCCN preferred regimens that name a single agent.

For ERISA plans, invoke the step-therapy override under 29 USC §1185d (CAA 2020) where the preferred agent was previously ineffective, contraindicated, or expected to cause harm. For commercial fully-insured plans, layer state external review. Cite Pinto v. Aetna Life Ins. Co., 10th Cir. 2014 — the plan bears the burden of showing the requested therapy is experimental or non-covered; NCCN Category 1/2A listings extinguish that burden as a matter of compendium-based medical necessity. Where Optum's internal reviewer overrides an NCCN Category 1 recommendation, that override is itself reviewable under Wit v. UBH (N.D. Cal. 2019; 9th Cir. 2023) reasoning — generally accepted standards of care control, not internal proprietary criteria.

Tactical tip: Submit the appeal through OptumRx specialty channel and simultaneously to UHC medical-benefit appeals (oncology requests bifurcate). Demand the full NCCN compendium printout for the exact indication line, the internal coverage determination guideline version number, and the reviewer's oncology board certification under §2560.503-1(h)(3)(iii). Missing reviewer credentials alone is grounds for remand.